Germline Panel – Colorectal Cancer

Test Code
SLS161005
Book Now

What is the Germline Panel - Colorectal Cancer?

Colorectal cancer is one of the most common cancers worldwide with an incidence of 1.9 million (Globocan 2022). Approximately 5–10% of colorectal cancers have an underlying hereditary cause. The Germline Panel – Colorectal Cancer identifies genetic mutations associated with hereditary colorectal cancer syndromes, such as Lynch syndrome, familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), and other inherited conditions that increase colorectal cancer risk. Early identification of these mutations enables tailored surveillance, risk-reducing strategies, and family testing.

Genes Covered/No of Genes: APC, BMPR1A, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, SMAD4, STK11, TP53

Indications for Testing

  • Individuals with colorectal cancer diagnosed before age 50.
  • Patients with multiple colorectal polyps (>10) or a family history of polyposis syndromes.
  • Individuals with a personal or family history of Lynch syndrome-related cancers.
  • Patients meeting Amsterdam or Bethesda criteria.

Inheritance Pattern

  • Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2, EPCAM) follow an autosomal dominant inheritance pattern.
  • FAP-associated APC mutations are also autosomal dominant, while MUTYH-associated polyposis (MAP) follows an autosomal recessive pattern.

Why is This Test Important?

Identifying inherited mutations allows for enhanced colorectal cancer screening, early intervention, and risk reduction strategies.
Colorectal Cancer

Contact Us